We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Sight Diagnostics

Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, c... read more Featured Products: More products

Download Mobile App





Machine Vision-Based Blood Analyzer Supports Validation of AI-based COVID Screening System

By LabMedica International staff writers
Posted on 15 Mar 2021
A machine vision-based blood analyzer has been made part of an assessment of an AI-based test to rapidly screen for COVID-19 in patients arriving in emergency departments.

Sight Diagnostics (Tel Aviv, Israel) has deployed Sight OLO at the John Radcliffe Hospital - part of the Oxford University Hospitals NHS Foundation Trust (Oxford, UK) that allows rapid FBC testing, in minutes, for patients attending the emergency departments and is supporting validation of a rapid AI triage system for COVID-19. More...
Sight OLO enables faster predictions to be generated by Oxford University’s ‘CURIAL AI’ screening test, which leverages patients’ routine vital signs and FBC results to predict the likelihood of a patient having COVID-19.

Developed by a cross-disciplinary team at Oxford University, the CURIAL algorithm has proven to be an effective triage tool that can rule-out COVID-19 within the first hour of patients coming to the hospital. Polymerase Chain Reaction (PCR) tests typically have a turnaround time of 12-48 hours and require specialist equipment and staff, while the more rapid lateral flow assays and antigen tests have produced mixed efficacy results. With CURIAL, Sight OLO could allow staff in emergency rooms to receive an accurate prediction to rule-out COVID-19 in under 30 minutes. About the size of a toaster oven, Sight OLO is compact and uses a cartridge-based system that does not require external reagents or routine calibration and maintenance, making it simple to set-up and operate wherever FBC is needed.

“Having accurate FBC results in minutes, from OLO, would help CURIAL make predictions even sooner, potentially reducing care delays and supporting infection control within hospitals. Our goal is to get the right treatment to patients sooner by helping rule-out Covid at triage for a majority of patients who don’t have the infection,” said Dr. Andrew Soltan, an Academic Clinician and a Machine Learning Researcher at Oxford University. “This project shows that artificial intelligence can work with rapid diagnostics to help us select the best care pathways and minimize risks of spreading the infection in hospitals.”

“We’re proud to collaborate with a cutting-edge institution like Oxford University on their CURIAL analysis program to help manage the effects of the pandemic,” said Yossi Pollak, CEO and Co-founder of Sight Diagnostics. “We see time and again when FBC results are made available to clinicians quickly and easily, patient care models are reconfigured for the better. The CURIAL project is a beacon of what’s possible, and we are keen to support other health institutions by enabling access to fast, convenient and accurate FBC through OLO.”

Related Links:
Oxford University Hospitals NHS Foundation Trust
Sight Diagnostics



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.